Analyst Thinks Johnson & Johnson Could Hit a $280 Target
A major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Identify whether a Backdoor Roth is right for you, focusing on income, taxes, and long-term retirement goals.
23,905 articlesA major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Vertiv CEO Giordano Albertazzi says liquid cooling capacity is expanding rapidly to support surging AI infrastructure...
A trio of high-yield names—PNNT, GLAD, and KRP—show divergent payout reliability even as yields approach double digit...
Bitcoin has fallen out of step with broad money growth, creating a large gap between its price and M2-derived fair va...
Two early Bitcoin holders liquidated $117 million in BTC on March 19, while big wallets doubled down on purchases in ...
Investors are shifting bets toward defense names as urban warfare tech dominates modernization plans. This piece exam...
Three AI ETFS split starkly in early 2026: one climbs while another fades, illustrating how fund design shapes AI bet...
Ethereum sits around $2,170 as the scaling debate intensifies. Analysts warn that a fragmented L2 path and security c...
ARK Invest placed a sizable bet on Circle amid a sell-off triggered by draft Clarity Act provisions. The move sparked...
New York’s 2025 bonuses hit an all-time high, with payouts topping $49.2 billion and the average near $247k. Yet the ...
A 2025 performance-year pay surge pushed the average wall street bonus to around $210,000, about three times the typi...
Washington moves to outlaw noncompete agreements statewide, imposing a 2027 deadline. The sweeping policy reshapes hi...